Lisette Delgado Sanchez, MD
Pulmonary Disease · Naples, FLNPI 1558523050
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $27,026 of the $32,361 with a category attached, or 83.5%. It is spread thinly across 51 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $9,448, 2.7 times the $3,534 reported in 2019. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,239 payments — averaging $26.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$6K
- AstraZeneca$5K
- GSK$3K
- Actelion Pharmaceuticals US, Inc.$2K
- Boehringer Ingelheim$2K
- Regeneron Healthcare Solutions, Inc.$2K
- plus $11K from 45 others
Across 461 payments — averaging $3397.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$565K
- Merck$374K
- GSK$270K
- AstraZeneca$245K
- Boehringer Ingelheim$88K
- CSL Behring$17K
- plus $7K from 1 others
What the payments were for
- Consulting fees$4,67714%
- Travel & lodging$1340%
- Food & beverage$27,02684%
- Education$5232%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,361 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 72 | $857,044 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 684 | $559,669 |
| Tyvaso DpiTreprostinil | 13 | $333,758 |
| Dupixent PenDupilumab | 69 | $258,612 |
| NucalaMepolizumab | 32 | $127,669 |
| Breo ElliptaFluticasone/Vilanterol | 202 | $115,547 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 134 | $101,257 |
| Spiriva RespimatTiotropium Bromide | 148 | $92,681 |
| Fasenra PenBenralizumab | 15 | $84,613 |
| TezspireTezepelumab-Ekko | 11 | $44,603 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 51 | $27,697 |
| Arnuity ElliptaFluticasone Furoate | 100 | $24,570 |
| Pirfenidone | 26 | $23,180 |
| Atrovent HfaIpratropium Bromide | 40 | $20,771 |
| Advair HfaFluticasone Propion/Salmeterol | 52 | $20,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $2,209 | $972,244253 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $3,056 | $869,4891,095 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Pulmicort Flexhaler | $5,281 | $172,809212 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $19 | $6,86016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Naples
- Edward SalernoNaples$154K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.